GT Biopharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
65.3%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.34next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Third Quarter 2026 Financial Results | 13 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly9MTarget: Sufficient to fund operations through Q4 2026
GTB-3650 Phase 1 Patient Enrollment Quarterly8.0Target: Up to approximately 14 patients across 7 dose cohorts
GTB-5550 Phase 1 Trial Progress Quarterly1.0Target: Dose escalation cohorts completion
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Closing bid price below $1.00 per shareAction: Regain compliance by closing at or above $1.00 for at least 10 consecutive business days before November 16, 2026, potentially via a reverse stock split (1-for-10 to 1-for-30 range).
- Going Concern and Capital RunwayTrigger: Cash runway depletion approaching Q4 2026Action: Secure additional equity, preferred stock, or debt financing to fund ongoing clinical trials and operations.
- Clinical Trial Updates for GTB-3650 and GTB-5550Trigger: Second Half of 2026 (2H 2026)Action: Present clinical safety, pharmacokinetic, and efficacy updates from the ongoing Phase 1 trials.
Research as of 20 Jun 2026